首页 | 本学科首页   官方微博 | 高级检索  
     

腹膜后淋巴结切除术对卵巢恶性生殖细胞肿瘤的治疗意义
引用本文:Jin Y,Pan LY,Huang HF,Shen K,Wu M,Yang JX,Lang JH. 腹膜后淋巴结切除术对卵巢恶性生殖细胞肿瘤的治疗意义[J]. 中国医学科学院学报, 2005, 27(6): 743-748
作者姓名:Jin Y  Pan LY  Huang HF  Shen K  Wu M  Yang JX  Lang JH
作者单位:中国医学科学院,中国协和医科大学,北京协和医院妇产科,北京,100730
摘    要:
目的探讨腹膜后淋巴结切除术在初治及复发卵巢恶性生殖细胞肿瘤(OGCT)患者中对肿瘤复发及患者生存的影响.方法回顾性分析我院1980年6月~2003年6月收治的OGCT患者102例,记录初治及复发手术时进行腹膜后淋巴结切除的情况、病理及其他可能与预后相关的因素.采用cox回归进行与肿瘤复发相关的单因素和多因素分析.结果在初治及复发病例中,腹膜后淋巴结转移与疾病预后无显著相关性.初治时肿瘤FIGO分期、化疗方案、手术彻底性和是否行腹膜后淋巴结切除术是影响疾病复发的显著性因素,其中化疗方案的影响最大.对化疗方案分层后,在博莱霉素 足叶乙甙 顺铂(BEP)或顺铂 长春新碱 博莱霉素(PVB)方案化疗时,是否行腹膜后淋巴结切除术与肿瘤复发无显著相关性,而在其他方案化疗组及未化疗者中,行腹膜后淋巴结切除术显著减少复发.在复发病例中仅手术彻底性与复发后生存时间相关,复发手术是否行腹膜后淋巴结切除术与复发后生存期无显著相关性.结论腹膜后淋巴结转移与OGCT的预后无明确的负相关性,对已进行手术而未行腹膜后淋巴结切除者,如已开始化疗,无须再次手术,可根据初次手术的结果行BEP或PVB方案规范化疗;对于初治患者,如有足够熟练的手术技巧,在尽量进行肿瘤细胞减灭的同时,应行该术式;对于复发患者,手术的目的是进行满意的肿瘤细胞减灭,腹膜后淋巴结切除意义有限.

关 键 词:卵巢生殖细胞肿瘤  淋巴结切除术  淋巴结转移  化疗
文章编号:1000-503X(2005)06-0743-06
收稿时间:2004-12-30
修稿时间:2004-12-30

Lymphadenectomy in the treatment of malignant ovarian germ cell tumor
Jin Ying,Pan Ling-ya,Huang Hui-fang,Shen Keng,Wu Ming,Yang Jia-xin,Lang Jing-he. Lymphadenectomy in the treatment of malignant ovarian germ cell tumor[J]. Acta Academiae Medicinae Sinicae, 2005, 27(6): 743-748
Authors:Jin Ying  Pan Ling-ya  Huang Hui-fang  Shen Keng  Wu Ming  Yang Jia-xin  Lang Jing-he
Affiliation:Department of Obstetrics and Gynecology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
Abstract:
OBJECTIVE: To evaluate the impact of lymphadenectomy on the relapse and survival of malignant ovarian germ cell tumor (OGCT). METHODS: The clinical data of 102 OGCT cases treated in Peking Union Medical College Hospital from June 1980 to June 2003 were analyzed retrospectively. All the data about lymphadenectomy during primary and secondary surgery were collected, and other factors related to prognosis were also collected at the same time. Chi-squared test was applied in the univariate analysis related to relapse of disease. Cox model was applied in multivariate analysis related to relapse and survival of disease. RESULTS: Pelvic and paraaortic lymph node metastasis was not significantly related to prognosis in primary and secondary treated patients. Lymphadenectomy showed no significant impact on disease relapse and survival. In the primary treatment, International Federation of Gynecology and Obstetrics (FIGO) staging, chemotherapy regimen, residual tumor and lymphadenectomy were the significant factors related to the relapse. After being stratified for the chemotherapy regimen, lymphadenectomy was not significantly related to the relapse in bleomycin +etoposide +cisplatin or cisplatin +vincristine +bleomycin regimen group, and lymphadenectomy could prevent relapse in no chemotherapy or other chemotherapy regimen group. In relapsed patients, only residual tumor was significantly related to survival time after relapse. CONCLUSIONS: Pelvic lymph node metastasis is not the significant risk factor related to prognosis. Lymphadenectomy may have a beneficial effect on survival, although such effect is not significant. Although lymphadenectomy provides important information for prognosis, they provide little benefit to those patients already requiring chemotherapy based on the original operative findings. Lymphadenectomy should be performed to primary or relapsed patients by an expert surgical team.
Keywords:ovarian germ cell tumor   lymphadenectomy   lymph node metastasis   chemotherapy
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号